Verve Therapeutics announced that the first patient has been dosed with VERVE-102 in the Heart-2 Phase 1b clinical trial. “Dosing the first patient in the Heart-2 Phase 1b clinical trial for VERVE-102 is an important step in the continued progress of our pipeline,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. “VERVE-102 is designed to turn off the PCSK9 gene with a goal of durably lowering LDL-C in patients living with either HeFH or premature CAD, and we look forward to evaluating the safety and preliminary efficacy data of VERVE-102 in the Heart-2 trial. With Clinical Trial Applications cleared in Canada and the United Kingdom, we are actively enrolling patients in the Heart-2 trial and expect to provide a data update on our PCSK9 program in 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics initiated with a Buy at H.C. Wainwright
- Verve Therapeutics price target lowered to $40 from $56 at Stifel
- Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
- RBC remains buyer of Verve Therapeutics after enrollment pause